At a Glance
- Company: OpenAI
- Location: US
- Focus area: Life sciences research and drug discovery
- Model: GPT-Rosalind
- Next steps: Research preview for qualified enterprise users
What happened?
OpenAI introduced GPT-Rosalind, a specialised reasoning model built for life sciences research across biology, drug discovery and translational medicine. The company says the model is designed to help researchers work across published evidence, data, tools and experiments more efficiently.
Why does it matter?
The launch gives drug developers a domain-specific AI tool aimed at some of the slowest parts of R&D, including target discovery, literature synthesis and experimental planning. OpenAI says the model is intended to speed up early-stage research, where better decisions can shape downstream biology, development timelines and ultimately clinical outcomes.
Who’s behind it?
GPT-Rosalind is OpenAI’s first model in a new life sciences series, named after scientist Rosalind Franklin. OpenAI says the system is being offered through enterprise channels with security and governance controls, and the company is already working with life sciences customers including Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific.
How was it achieved?
The model is built for multi-step scientific workflows, including genomics interpretation, pathway analysis, protein understanding and biochemistry reasoning. OpenAI also released a life sciences research plugin for Codex that connects users to more than 50 public databases, literature sources and biology tools.
What’s next?
GPT-Rosalind is being rolled out as a research preview for qualified users, with broader pricing and availability to follow later. OpenAI says this is the first release in a broader life sciences model series, suggesting more specialised scientific AI tools are likely to follow.